Atlas Trials

Selective HDAC6 Inhibitor ACY 241 in Combination With Nivolumab in Patients With Unresectable Non Small Cell Lung Cancer

Clinical trial NCT02635061 · TERMINATED

Trial details

NCT number
NCT02635061
Sponsor
Celgene
Status
TERMINATED
Phase
Phase 1
Study type
INTERVENTIONAL
Non Small Cell Lung Cancer
Start date
2016-08-25
Primary completion
2024-01-22
Enrollment
17

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.